BusinessFate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 StageBy Nasdaq OMXDec 11, 2017, 11:13 PM UTC
BusinessFate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500By Nasdaq OMXDec 11, 2017, 9:30 PM UTC
BusinessFate Therapeutics to Present at the Needham & Company 15th Annual Healthcare ConferenceBy Nasdaq OMXApr 5, 2016, 8:01 PM UTC
BusinessFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016By Nasdaq OMXFeb 25, 2016, 9:01 PM UTC
